Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 18, 2023 | May 19, 2023 |
| Generate Biomedicines, Inc.GENB · Entity 1553 | Director | February 26, 2026 | March 02, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | June 14, 2022 | June 16, 2022 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 05, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 18, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $189.87 · Expires 2033-05-18 | Direct | 3,454 |
Reported balance
After 2023-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-18 · Grant · Acquired 3,454 · Balance 3,454 F1: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Korsana Biosciences, Inc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2032-06-14 | Direct | 20,000 |
Reported balance
After 2022-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 20,000 · Balance 20,000 F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.
Syros Pharmaceuticals, Inc.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,000 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 4,000 · Balance 16,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2034-06-04 | Direct | 6,000 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Grant · Acquired 6,000 · Balance 6,000 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forma Therapeutics Holdings, Inc.
Report date October 14, 2022 · Filed October 14, 2022
Section 16 reporting ended · disclosed 2022-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-10-14 · Other · Disposed 52,532 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-10-14 · Other · Disposed 7,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.05 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-14 · Disposition to issuer · Disposed 14,026 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-14 · Disposition to issuer · Disposed 28,053 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-14 · Disposition to issuer · Disposed 17,533 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.35 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-14 · Disposition to issuer · Disposed 8,375 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-14 · Disposition to issuer · Disposed 6,750 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.
F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 132,663 |
Reported balance
After 2019-04-01 transaction · row 1
1 source rowRow 1 · 2019-04-01 · Disposition to issuer · Disposed 4,056 · Balance 132,663 F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2019 Filed Apr 3, 2019 21:08 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 3,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023565 · doc4a.xml · nonDerivative · entry 2 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 F2 · shares: Represents shares of Cyclerion common stock granted to the reporting person as a result of adjustments to existing Ironwood shares of common stock made in connection with the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:08 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023565 · doc4a.xml · nonDerivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,671 F1 · shares: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:32 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 3,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023507 · doc4.xml · nonDerivative · entry 2 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 F2 · shares: Represents shares of Cyclerion common stock granted to the reporting person as a result of adjustments to existing Ironwood shares of common stock made in connection with the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:32 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023507 · doc4.xml · nonDerivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,671 F1 · shares: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 00:59 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherClass A Common Stock | 44,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-001491 · doc4.xml · nonDerivative · entry 2 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,719 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 00:59 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherClass B Common Stock | 44,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-001491 · doc4.xml · nonDerivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $105.26 | $0.00 |
DisclosureSEC source: 0001735276-18-000029 · edgardoc.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:28 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001179110-18-008619 · edgar.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 16,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035246 · doc4.xml · nonDerivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,856 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:04 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001179110-17-008900 · edgar.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 08, 2017 Filed Sep 22, 2017 17:19 UTC Amendment | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001179110-17-012627 · edgar.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F2 · derivative.exercise_price: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:56 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $71.99 | $0.00 |
DisclosureSEC source: 0001553878-17-000024 · edgardoc.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:58 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037351 · doc4.xml · nonDerivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,633 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 06:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001104659-16-145300 · a4.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Ms. Fanucci's continued service as a director through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.